Schwannomatosis, also known as neurofibromatosis type 2, is an inherited disorder characterized by the formation of multiple benign tumors that arise from nerve sheaths known as Schwann cells. These tumors, called schwannomas, can form on peripheral nerves as well as the auditory and vestibular nerves, which can lead to serious neurological consequences such as hearing loss and balance problems. The disease is associated with mutations in the NF2 gene, located on chromosome 22, and manifests itself with varying degrees of severity depending on individual factors. There are both sporadic cases and inherited forms of the disease, which requires an in-depth approach to diagnosis and treatment.
History of the disease and interesting historical facts
The history of schwannomatosis research dates back to the late 19th century, when cases of tumors arising from nerve sheaths were first reported. In the 1930s, relatives with hereditary forms of the disease were described, which gave rise to systematic studies. Significant contributions to the understanding of schwannomatosis were made by scientists such as Linnchild and Ingle, who described the clinical manifestations and genetic nature of the disease. Interestingly, the term neurofibromatosis is often incorrectly used to describe schwannomatosis, while the two diseases have different genetic bases and clinical manifestations.
Epidemiology
Schwannomatosis occurs with a frequency of approximately 1 in 25,000 people worldwide. The disease is predominantly diagnosed in people aged 20 to 30 years, but symptoms can appear earlier, even in childhood. Men and women suffer from schwannomatosis with approximately equal frequency. Notably, about half of the cases of schwannomatosis become clinically apparent in adolescence, while the remaining cases may manifest later. A number of studies show that in hereditary variants of schwannomatosis, the incidence is higher in families with a known history of the disease.
Genetic predisposition to this disease
Schwannomatosis is caused by mutations in the NF2 gene, which codes for the protein mertinin, which plays a key role in regulating cell growth. The main mutations include deletions, point mutations, and insertions affecting functional regions of this gene. In twins of different origin, it has been noted that if one of them has schwannomatosis, the risk of the other twin developing the disease is significantly higher, indicating a genetic predisposition. It is important to note that about 50% cases of schwannomatosis are sporadic, while other cases are transmitted in an autosomal dominant manner.
Risk factors for the development of this disease
Both genetic and environmental factors influence the development of schwannomatosis. The main risk factors include:
- Having a family history of schwannomatosis.
- Age – cases occur more often in middle-aged patients.
- Previously diagnosed neurofibromatosis type 1, which may be associated with schwannomatosis.
- Possible external influences, such as radiation or viral infections, which, according to some data, may influence the development of tumors.
Physiological and chemical risk factors have been studied in detail, but the exact mechanisms of their influence on the development of schwannomatosis remain the subject of further research.
Diagnosis of this disease
Diagnosis of schwannomatosis is based on clinical findings and should include:
- The main symptoms are hearing loss, dizziness and neurological disorders.
- Lab tests: Genetic testing for mutations in NF2.
- Radiological examinations: MRI and CT to visualize schwannomas.
- Other types of diagnostics: audiometric tests to assess hearing impairment.
- Differential diagnosis should be made with neurofibromatosis type 1 and other tumors of the nervous tissue.
The difficulty of diagnosis lies in the fact that schwannomatosis can have mild manifestations and requires a careful approach to establish a definitive diagnosis.
Treatment
Treatment of schwannomatosis requires an individual approach and may include:
- General treatment: observation of the patient's condition and control of symptoms.
- Pharmacological treatment: use of non-steroidal anti-inflammatory drugs to reduce pain.
- Surgical treatment: removal of schwannomas, which can significantly improve the patient's quality of life.
- Other treatments: Use of radiotherapy in cases where surgery is not appropriate.
It is important to note that the choice of treatment method should be based on the severity of the disease and clinical symptoms.
List of medications used to treat this disease
The main drugs used in the treatment of schwannomatosis include:
- Nonsteroidal anti-inflammatory drugs (eg, Ibuprofen)
- Pain analgesics for the management of pain symptoms.
- Drugs for improving metabolism in nervous tissues.
- Immunomodulators in some cases.
Therapy depends on specific symptoms and is selected by a doctor based on individual indications.
Disease monitoring
Monitoring a patient with schwannomatosis involves regular check-ups and follow-up steps, which may include:
- Periodic audiometric tests to assess hearing.
- MRI to monitor tumor growth.
- Assessment of neurological functions.
- Discussion of possible complications such as hearing loss or neurological impairment.
The prognosis depends on the severity of the disease, the rate of tumor growth and the quality of medical care.
Age-related features of the disease
Schwannomatosis can manifest itself at any age, but the course of the disease differs between adults and children. In children, the disease may manifest itself more aggressively, while in adults, tumors often grow slowly and symptoms are less pronounced. It is important to monitor the condition even in people who have reached childhood and adolescence, since early diagnosis can significantly improve the prognosis.
Questions and Answers
- What are the main symptoms of schwannomatosis? The main symptoms include hearing loss, dizziness and pain syndromes resulting from pressure on the nerve endings.
- How is schwannomatosis diagnosed? Diagnosis includes clinical examination, genetic testing, and radiological examination, especially MRI.
- What is the prognosis for patients with schwannomatosis? The prognosis varies, but in most cases, with proper treatment, patients can have a good quality of life.
- What treatment is most effective? Surgery is the most effective method for removing tumors when symptoms are severe.
- Can schwannomatosis become malignant? In most cases, schwannomatosis is benign, but there may be situations that require careful monitoring and treatment.
